A recent case report in the Journal of Neurosurgery indicates that bleeding complications from Boehringer Ingelheim's blood clot preventer, Pradaxa, may be irreversible. The report describes the death of an 83 year old man who had a routine ground level fall at home. He had been started on dabigatran, known by the commercial name Pradaxa, one month earlier for atrial fibrillation. Atrial fibrillation is known to increase the risk of stroke and death.
The man was initially alert and oriented when he arrived in the emergency room, and his neurological exam produced no great concern. His CT scans showed small, superficial areas of hemorrhage in his brain. However, within two hours he experienced extensive progression of hemorrhaging in his brain which could not be stopped. He fell into a deep coma and soon died.
Pradaxa was approved in the United States in October 2010 for stroke prevention in patients with atrial fibrillation. The case report indicates that Pradaxa presents a dilemma for neurosurgeons because the patients receiving it are often elderly and commonly experience falls. As Pradaxa use becomes widespread, intracranial hemorrhage from even minor trauma may become more frequent and no effective drug to reverse its effects is presently available.
If you suspect that Pradaxa was the cause of injury to you or a loved one, please contact the dangerous drug attorneys at the Taylor Law Firm
. We are evaluating Pradaxa cases nationwide, especially in the states of Alabama, Mississippi, Florida
, and the cities of Mobile, Pensacola, Biloxi, Gulfport
, and can advise you on your legal rights concerning this potentially dangerous drug. Please email us
or call us at 855.646.4355
to discuss your concerns.